Search

Displaying results 6361 - 6370 of 7017 in total
  1. Drug

    Rimtuzalcap

    go.drugbank.com/drugs/DB16733
    Investigational

    Rimtuzalcap is a novel modulator of small-conductance calcium-activated potassium channels that is under investigation for the treatment of essential tremor.[L38414]

  2. Drug

    ENMD-1198

    go.drugbank.com/drugs/DB05959
    Experimental

  3. Drug

    Pefloxacin

    go.drugbank.com/drugs/DB00487
    Approved

    A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.

  4. Drug

    Erythrityl tetranitrate

    go.drugbank.com/drugs/DB01613
    ApprovedWithdrawn

    A vasodilator with general properties similar to nitroglycerin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1020)

  5. Drug

    Armodafinil

    go.drugbank.com/drugs/DB06413
    ApprovedInvestigational

    (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.

    Products: ARVIGIL FT COMPRIMIDOS 200MG
  6. Drug

    ARG098

    go.drugbank.com/drugs/DB06338
    Experimental

    ARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.

  7. Drug

    Atibuclimab

    go.drugbank.com/drugs/DB06546
    Investigational

    Atibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.

  8. Drug

    Methoxy polyethylene glycol-epoetin beta

    go.drugbank.com/drugs/DB09107
    ApprovedInvestigational

    Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Tariquidar

    go.drugbank.com/drugs/DB06240
    Investigational

  10. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. … LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.